Welcome to our dedicated page for Wave Life Sciences Ltd. Ordinary Shares news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Sciences Ltd. Ordinary Shares stock.
Wave Life Sciences Ltd. (Nasdaq: WVE) is a clinical-stage biotechnology company harnessing its groundbreaking synthetic chemistry platform to create stereopure nucleic acid therapeutics. Focused on rare genetic diseases, Wave's pipeline addresses conditions such as alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy (DMD), and Huntington's disease. Wave's proprietary PRISMTM platform integrates various RNA modalities, including RNA editing, antisense, exon-skipping, and RNA interference, enabling scientific breakthroughs that address both rare and common disorders.
Recently, Wave has made significant progress with its Phase 2 FORWARD-53 trial for DMD, showing promising results with WVE-N531. This trial, which began dosing in December 2023, aims to evaluate dystrophin protein generation in boys amenable to exon 53 skipping, with critical data expected in 2024. The company also anticipates delivering first-of-its-kind RNA editing proof-of-mechanism data in 2024 for its WVE-006 program, targeting alpha-1 antitrypsin deficiency.
Financially, Wave is well-capitalized, with substantial cash inflows and strategic partnerships, including a notable collaboration with GSK. This partnership has led to significant milestone payments and the initiation of development programs utilizing Wave's advanced GalNAc-siRNA format.
Wave Life Sciences is at the forefront of RNA medicine, driven by a commitment to transform human health and provide life-changing treatments for devastating diseases.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced the publication of preclinical data revealing their small interfering RNA (siRNA) designs demonstrate superior potency and durability for gene silencing compared to comparator formats. In a study, a Wave siRNA maintained approximately 80% silencing of HSD17B13 transcripts in transgenic mice for three months, contrasting with 60% silencing observed in a comparator siRNA which returned close to baseline by three months. The study highlighted a significant 10-fold increase in Ago2 loading with Wave’s siRNA due to innovative PN backbone modifications. This advancement reaffirms Wave's potential in RNAi therapeutics and its collaboration with GSK, reflecting a commitment to developing cutting-edge genetic medicines.
Wave Life Sciences (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on April 3, 2023, at 2:10 p.m. ET. The event aims to discuss the company's commitment to developing innovative genetic medicines for serious diseases.
A live webcast of the presentation will be accessible on the Investor Relations page of their corporate website, with an archived replay available for a limited period post-event.
Wave Life Sciences (WVE) reported its financial results for Q4 and the full year 2022, highlighting a net loss of $43.7 million in Q4 and $161.8 million for the year, attributed mainly to increased clinical program expenses. The company achieved clinical validation of its PRISM platform and advanced WVE-006, its first RNA editing candidate, into clinical development for AATD. A strategic collaboration with GSK may yield up to $3.3 billion in milestone payments. Wave has a solid cash position with $88.5 million available, expected to sustain operations into 2025. Key upcoming milestones include new clinical data in 2023.
Wave Life Sciences Ltd. (Nasdaq: WVE) has announced a live webcast and conference call scheduled for 8:30 a.m. ET on March 22, 2023, to discuss its fourth quarter and full year 2022 financial results, along with a business update. Analysts can participate in a Q&A session during the call. The call will be accessible through the investor relations section of their website. Additionally, an archived version of the webcast will be available afterward. Wave Life Sciences focuses on developing genetic medicines using its proprietary PRISM platform, targeting a range of genetically defined diseases.
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that CEO Paul Bolno will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 16, 2023, at 10:00 a.m. ET.
The event will be streamed live and available for later viewing on the company's Investor Relations page. Wave Life Sciences is focused on developing life-changing treatments for genetically defined diseases using its PRISM platform, which facilitates the design and production of stereopure oligonucleotides.
Wave Life Sciences (WVE) announced positive results from its Phase 1b/2a study of WVE-N531 in Duchenne muscular dystrophy (DMD). The study showed a mean exon skipping rate of 53% and a tissue concentration of 42 micrograms/gram after six weeks of biweekly dosing at 10 mg/kg. While dystrophin levels were below detection limits, safety and tolerability were confirmed with only mild adverse events. The company plans to evaluate next steps for WVE-N531 following this encouraging proof-of-concept data.
Wave Life Sciences announces a strategic collaboration with GSK to advance oligonucleotide therapeutics, including WVE-006 for alpha-1 antitrypsin deficiency (AATD). The partnership involves an upfront payment of $170 million, comprising $120 million in cash and $50 million in equity, with potential milestone and royalty earnings exceeding $500 million. Wave will leverage its PRISM platform alongside GSK's expertise to progress multiple programs over an initial four-year term, enhancing its pipeline and extending its cash runway into 2025.
Wave Life Sciences announced key developments in its third quarter 2022 report, highlighting progress in clinical trials for Huntington’s disease (WVE-003) and Duchenne muscular dystrophy (WVE-N531). The SELECT-HD trial showed safe, well-tolerated doses and a reduction in mutant huntingtin protein. WVE-006 was selected for alpha-1 antitrypsin deficiency, with CTA submissions expected in 2023. Financially, the company reported a net loss of $39 million and a significant revenue drop to $0.3 million, mainly due to prior collaboration amendments. Cash on hand is $122 million, expected to last through 2023.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on November 16, 2022, at 3:35 p.m. ET. This event focuses on the company's commitment to developing genetic medicines for devastating diseases. A live webcast of the discussion will be available on the company’s Investor Relations page, with replays accessible for a limited time post-event.
Wave Life Sciences (Nasdaq: WVE) announced a conference call scheduled for 8:30 a.m. ET on November 10, 2022, to discuss its Q3 2022 financial results and provide a business update. The call will be accessible via the company’s investor relations webpage. Wave Life Sciences is a clinical-stage genetic medicines company focused on developing treatments for severe diseases using its proprietary PRISM platform for drug development. The archived call will also be available post-event.
FAQ
What is the current stock price of Wave Life Sciences Ltd. Ordinary Shares (WVE)?
What is the market cap of Wave Life Sciences Ltd. Ordinary Shares (WVE)?
What is Wave Life Sciences Ltd.?
What diseases is Wave targeting?
What is the PRISMTM platform?
What is the FORWARD-53 trial?
What recent achievements has Wave Life Sciences made?
How is Wave Life Sciences funded?
What is WVE-006?
What is the significance of the partnership with GSK?
What is Wave's approach to RNA medicines?
Where is Wave Life Sciences headquartered?
